RxDoctor Payments Data

Dahlia Sano, MD

Hematology · Ann Arbor, MINPI 1659631729

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Seagen Inc. at 50.4% of the total. Reporting peaked in 2021 at $1,225 and has fallen 87.6% since, to $152 in 2025.

$2,578in general payments, 2019–2025

Across 13 payments — averaging $198.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$1K
  • Novartis$888
  • Icotec Medical Inc.$152
  • Johnson & Johnson$99
  • Adaptive Biotechnologies Corporation$90
  • Beigene USA, Inc.$50
$2,999,121in research payments, 2019–2025

Across 255 payments — averaging $11,761 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$1.1M
  • Pharmacyclics LLC, An Abbvie Company$543K
  • Seagen Inc.$352K
  • Pfizer$296K
  • Beone Medicines Ltd.$262K
  • Epizyme, Inc.$139K
  • plus $279K from 8 others

What the payments were for

  • Consulting fees$1,22548%
  • Travel & lodging$67826%
  • Food & beverage$57522%
  • Education$994%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,578 in reported general payments places this provider in the 60th percentile of 50 hematology providers in Michigan.

See all hematology providers in Michigan

Medicare billing

Part B allowed, 2024
$20,889
Medicare patients
99
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib33$414,893
Atovaquone13$2,556
Entecavir12$1,150
Acyclovir67$1,102
Famotidine27$340
Prednisone49$167
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$156
Ondansetron Hcl24$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$50$414,89333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 50 hematology providers in Michigan.

Other hematology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →